Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 1.00 |
| ▸ | RAF1 | P04049 | 1/20 | 1.00 |
| ▸ | BRAF | P15056 | 1/20 | 1.00 |
| ▸ | EPHB2 | P29323 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 0.76 |
| ▸ | ABL2 | P42684 | 1/20 | 0.76 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.76 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2083466 | 1.00 | MAPK14 (1.00) | MAPK14RAF1BRAFEPHB2ABL1 | |
| SCHEMBL2083701 | 0.93 | MAPK14 (0.86) | MAPK14RAF1BRAFEPHB2ABL1 | |
| SCHEMBL2081138 | 0.92 | MAPK14 (0.84) | MAPK14RAF1BRAFEPHB2ABL1 | |
| SCHEMBL2083763 | 0.92 | MAPK14 (0.84) | MAPK14RAF1BRAFEPHB2ABL1 | |
| SCHEMBL2080552 | 0.91 | MAPK14 (0.83) | MAPK14RAF1BRAFEPHB2ABL1 | |
| SCHEMBL2080595 | 0.91 | MAPK14 (0.83) | MAPK14RAF1BRAFEPHB2ABL1 | |
| SCHEMBL2083977 | 0.91 | MAPK14 (0.83) | MAPK14RAF1BRAFEPHB2ABL1 | |
| SCHEMBL2082836 | 0.90 | MAPK14 (0.82) | MAPK14RAF1BRAFEPHB2ABL1 | |
| SCHEMBL2081764 | 0.89 | MAPK14 (0.80) | MAPK14RAF1BRAFEPHB2ABL1 | |
| SCHEMBL2083083 | 0.89 | MAPK14 (0.79) | MAPK14RAF1BRAFEPHB2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118845789-A | Application of SRC inhibitor in preparation of medicines for inhibiting cell aging | 中国人民解放军总医院第二医学中心 | 2024-10-29 | — | — | CN | claimed |
| US-20250347680-A1 | METHODS OF OPTIMIZING KINASE INHIBITORS | BRANDEIS UNIVERSITY (US) | 2025-11-13 | — | — | US | disclosed |
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| CN-118845789-A | Application of SRC inhibitor in preparation of medicines for inhibiting cell aging | 中国人民解放军总医院第二医学中心 | 2024-10-29 | — | — | CN | disclosed |
| CN-118845789-A | Application of SRC inhibitor in preparation of medicines for inhibiting cell aging | 中国人民解放军总医院第二医学中心 | 2024-10-29 | — | — | CN | disclosed |
| US-11891457-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-06 | — | — | US | disclosed |
| CN-114425022-A | Automatic radioactive liquid medicine subpackaging system and method | 西安交通大学医学院第一附属医院 | 2022-05-03 | — | — | CN | disclosed |
| CN-215773550-U | Bluetooth TWS earphone PCB board carries antenna | 深圳市凌瑞特科技有限公司 | 2022-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891457-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | MAPK14 2342/4885RAF1 3631/4885BRAF 3712/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | MAPK14 2342/4885RAF1 3631/4885BRAF 3712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.